Stock Price Quote

DISHMAN CARBOGEN AMCIS LTD.

NSE : DCALBSE : 540701ISIN CODE : INE385W01011Industry : Pharmaceuticals & DrugsHouse : Dishman Pharma
BSE161.05-0.5 (-0.31 %)
PREV CLOSE ( ) 161.55
OPEN PRICE ( ) 160.95
BID PRICE (QTY) 160.65 (81)
OFFER PRICE (QTY) 161.10 (9)
VOLUME 7271
TODAY'S LOW / HIGH ( )157.40 162.70
52 WK LOW / HIGH ( )132.75 282.95
NSE160.11-1.51 (-0.93 %)
PREV CLOSE( ) 161.62
OPEN PRICE ( ) 159.00
BID PRICE (QTY) 160.20 (24)
OFFER PRICE (QTY) 160.42 (13)
VOLUME 157392
TODAY'S LOW / HIGH( ) 157.30 163.00
52 WK LOW / HIGH ( )133 283
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 2007
Management Info
Janmejay R Vyas - Chairman Arpit J Vyas - Managing Director
Registered Office

Address Dishman Corporate House,Iscon - Bopal Road,Ambli,
Ahmedabad,
Gujarat-380058

Phone 02717 420102 / 124

Email dishman@dishmangroup.com

Website www.dishmangroup.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

25May Dishman Carbogen Amcis planning to rai
Dishman Carbogen Amcis is planning to raise funds by way of issuance of..
03Feb Dishman Carbogen Amcis informs about d
Dishman Carbogen Amcis has informed that it attached the disclosure purs..
22Sep Dishman Carbogen Amcis informs about c
Dishman Carbogen Amcis has informed that as per Code of Conduct for prev..
15May Dishman Carbogen Amcis informs about b
Pursuant to Regulation 29 and 50 of SEBI (Listing Obligations and Disclo..
17Feb Dishman Carbogen Amcis moves up as its
Dishman Carbogen Amcis is currently trading at Rs. 103.30, up by 1.90 po..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit-311.2-764.1
Gross Profit -336.3 -1030
Operating Profit 83.5999999999999698.5
Net Sales 1112.63273.5

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  27931.25 (1.91%)
M.Cap ( in Cr)59219.15
Dr. Reddy's Lab (BSE)
peergroup  6773.40 (2.02%)
M.Cap ( in Cr)112776.88
Neuland Laboratories (BSE)
peergroup  8214.40 (1.10%)
M.Cap ( in Cr)10609.61
RPG Life Sciences (BSE)
peergroup  1875.00 (4.67%)
M.Cap ( in Cr)3207.66
Orchid Pharma (BSE)
peergroup  1381.50 (6.39%)
M.Cap ( in Cr)7097.89

Shareholding Pattern

PROMOTERS 59.32%
NON-INSTITUTION 29.62%
MUTUAL FUNDS/UTI 2.17%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Dishman Carbogen Amcis Ltd.

Dishman Carbogen Amcis Ltd. was incorporated in the year 2007. Its today's share price is 161.05. Its current market capitalisation stands at Rs 2526.56 Cr. In the latest quarter, company has reported Gross Sales of Rs. 4025.5 Cr and Total Income of Rs.4547.1 Cr. The company's management includes Shrima G Dave, Maitri Mehta, Rajendra S Shah, Subir Kumar Das, Arpit J Vyas, Deohooti J Vyas, Janmejay R Vyas.

It is listed on the BSE with a BSE Code of 540701 , NSE with an NSE Symbol of DCAL and ISIN of INE385W01011. It's Registered office is at Dishman Corporate House,Iscon - Bopal Road,AmbliAhmedabad-380058, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Haribhakti & Co LLP, Kunte & Associates., TR Chadha & Co LLP, VD Shukla & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.